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ABSTRACT: The slow afterhyperpolarizing current (sIAHP) is a calcium-
dependent potassium current that underlies the late phase of spike frequency
adaptation in hippocampal and neocortical neurons. sIAHP is a well-known tar-
get of modulation by several neurotransmitters acting via the cyclic AMP
(cAMP) and protein kinase A (PKA)-dependent pathway. The neuropeptide
pituitary adenylate cyclase activating peptide (PACAP) and its receptors are
present in the hippocampal formation. In this study we have investigated the
effect of PACAP on the sIAHP and the signal transduction pathway used tomod-
ulate intrinsic excitability of hippocampal pyramidal neurons. We show that
PACAP inhibits the sIAHP, resulting in a decrease of spike frequency adaptation,
in rat CA1 pyramidal cells. The suppression of sIAHP by PACAP is mediated by
PAC1 and VPAC1 receptors. Inhibition of PKA reduced the effect of PACAP on
sIAHP, suggesting that PACAP exerts part of its inhibitory effect on sIAHP by
increasing cAMP and activating PKA. The suppression of sIAHP by PACAP was
also strongly hindered by the inhibition of p38 MAP kinase (p38 MAPK). Con-
comitant inhibition of PKA and p38 MAPK indicates that these two kinases act
in a sequential manner in the same pathway leading to the suppression of sIAHP.
Conversely, protein kinase C is not part of the signal transduction pathway used
by PACAP to inhibit sIAHP in CA1 neurons.Our results show that PACAP enhan-
ces the excitability of CA1 pyramidal neurons by inhibiting the sIAHP through
the activation of multiple signaling pathways, most promi-
nently cAMP/PKA and p38 MAPK. Our findings disclose a
novel modulatory action of p38 MAPK on intrinsic excit-
ability and the sIAHP, underscoring the role of this current
as a neuromodulatory hub regulated by multiple protein
kinases in cortical neurons. VC 2013 The Authors. Hippo-
campus Published byWiley Periodicals, Inc.
KEY WORDS: hippocampus; slow afterhyperpolari-
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INTRODUCTION
Action potentials in hippocampal pyramidal neurons
are followed by an afterhyperpolarization (AHP) that has
three kinetically distinct phases: fast (fAHP), medium
(mAHP), and slow AHP (sAHP) (reviewed in Sah and
Faber, 2002; Stocker et al., 2004). The sAHP has a time-
course of seconds (1–5 s), is evident after bursts of action
potentials, and its amplitude is enhanced with increasing
number of spikes in the burst (Alger and Nicoll, 1980;
Hotson and Prince, 1980; Schwartzkroin and Stafstrom,
1980; Lancaster and Adams, 1986). The sAHP is medi-
ated by a slow calcium-dependent potassium current,
sIAHP, that contributes to the late phase of spike fre-
quency adaptation in hippocampal pyramidal neurons
(Madison and Nicoll, 1982; Lancaster and Adams,
1986; Lancaster and Nicoll, 1987). A trademark feature
of the sIAHP is its modulation by several neurotrans-
mitters activating various signal transduction pathways.
The modulation of sIAHP by monoamine transmitters
through the cyclic AMP (cAMP)-protein kinase A
(PKA) pathway has been extensively studied (reviewed in
Stocker et al., 2004). Beside monoamine transmitters,
some neuropeptides expressed in interneurons and
released in the hippocampal formation inhibit the sIAHP
and reduce spike frequency adaptation in pyramidal neu-
rons. These include the vasoactive intestinal peptide
(VIP, Haas and Gahwiler, 1992), the corticotropin releas-
ing factor (CRF, Aldenhoff et al., 1983) and the calcito-
nin gene-related peptide (CGRP, Haug and Storm,
2000), all exerting their inhibitory action on sIAHP via
the cAMP-PKA pathway (Haug and Storm, 2000).
The neuropeptide pituitary adenylate cyclase-
activating polypeptide (PACAP) belongs to a
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superfamily of structurally related peptide hormones that
include glucagon, glucagon-like peptides, secretin and growth
hormone-releasing hormone (Harmar, 2001). PACAP consists
of two isoforms, PACAP-27 with 27 and PACAP-38 with 38
amino acids, sharing identical sequences for the initial 27 amino
acids. Both isoforms were first identified and isolated from ovine
hypothalamic tissue (Miyata et al., 1989, 1990) and subse-
quently found to be preserved from protochordates to mammals
(Vaudry et al., 2009). PACAP exhibits a wide range of functions
and acts as a neurotransmitter and trophic factor in the CNS
(Vaudry et al., 2009). The first 28 amino acids of PACAP-38
show 68% sequence identity with VIP (Miyata et al., 1989,
1990), suggesting that VIP and PACAP might mediate their bio-
logical effects through shared receptors. Two classes of PACAP
receptors have been characterized based on their relative affinity
for PACAP and VIP. PACAP has a potency >100-fold higher
than VIP at the recombinant PAC1 receptor, whereas it displays
a potency similar to VIP at the recombinant VPAC receptors
(VPAC1 and VPAC2) in radioligand binding assays (reviewed in
Vaudry et al., 2009; Harmar et al., 2012). PAC1 and VPAC
receptors are coupled to the heterotrimeric G-protein Gas and
increase cAMP levels (reviewed in Harmar, 2001).
PACAP and its receptors are widely expressed in the CNS.
PACAP mRNA (Skoglosa et al., 1999; Jaworski and Proctor,
2000; Hannibal, 2002) and immunoreactivity (Koves et al., 1991;
Piggins et al., 1996; Hannibal, 2002) have been observed in the
rat hippocampus, in the cell body layers of the CA1-CA3 fields, in
dentate gyrus granule cells, mossy cells and pyramidal basket cells.
Additionally, PACAP immunoreactive fibers have been detected
both in the CA1-CA3 fields and in the dentate gyrus. In the hip-
pocampus, PACAP might therefore be released by neurons
(pyramidal cells or interneurons) within the hippocampal forma-
tion and/or by afferents coming from PACAP-rich regions, such
as the hypothalamus (Piggins et al., 1996). Northern blot analysis
and in situ hybridization revealed the presence of PAC1 (Hashi-
moto et al., 1993; Spengler et al., 1993), VPAC1 (Ishihara et al.,
1992) and VPAC2 (Lutz et al., 1993) receptor mRNA in the hip-
pocampal formation. Moreover, PACAP binding sites and recep-
tors were detected in the CA1-CA3 regions and dentate gyrus of
the hippocampus in autoradiographic studies (Cauvin et al., 1991;
Masuo et al., 1992). Immunohistochemistry showed that VPAC2
receptors were highly expressed in dentate gyrus granule cells and
in CA1-CA3 pyramidal cells, whilst PAC1 and VPAC1 were
expressed in the same cells but at lower levels (Joo et al., 2004).
The presence of PACAP and PACAP receptors in the hippo-
campus prompted us to hypothesize that PACAP might modu-
late the sIAHP in hippocampal pyramidal neurons, thereby
affecting their excitability and firing pattern. In this study we
have investigated the effect of PACAP on the sIAHP and the sig-
nal transduction pathway used in rat CA1 pyramidal neurons.
MATERIALS AND METHODS
Male Sprague Dawley rats, 21- to 24-days old, were used to
prepare transverse hippocampal brain slices. Rats were anesthe-
tized with isoflurane and decapitated according to the UK
Home Office Animal Scientific Procedures Act (1986), and
protocols were reviewed and approved by the University Col-
lege London Animal Ethical Committee.
Whole-cell patch clamp recordings were performed from
CA1 pyramidal neurons using the blind patching technique
(Blanton et al., 1989). All whole-cell patch clamp recordings
were conducted with an EPC10 amplifier (HEKA, Germany)
and the software Pulse for data acquisition. Slices were perfused
with ACSF (in mM: 125 NaCl, 1.25 KCl, 2.5 CaCl2, 1.5
MgCl2, 1.25 KH2PO4, 25 NaHCO3, and 16 glucose) and the
sIAHP was recorded at room temperature with patch pipettes
made of borosilicate glass and containing a gluconate-based
intracellular solution (in mM: 135 K-gluconate, 10 KCl, 10
HEPES, 1 MgCl2, 2 ATP-Na, and 0.4 GTP-Na). The liquid
junction potential for the intracellular solution is 211 mV.
Voltage values reported here are not corrected for the liquid
junction potential. Only cells with a resting membrane poten-
tial 250 mV and a series resistance 30 MX were included
in this study.
The sIAHP was elicited by stepping to 110–30 mV for 100–
150 ms from a holding potential of 250 mV. Recordings were
performed in the presence of 0.5 mM tetrodotoxin (TTX) to
block voltage-gated sodium channels, and 1 mM tetraethylam-
monium (TEA) to block a subset of voltage-gated potassium
channels to increase the calcium influx and thereby the calcium
dependent sIAHP. Traces were filtered at 0.25 kHz and sampled
at 1.25 kHz and the stimulus was repeated with a 30 s interval.
Bovine serum albumin (BSA) was added to the ACSF (25 mg
ml21) when peptides were used extracellularly to minimize
unspecific binding. Peptides were applied by bath perfusion. It
is worth noticing that the actual concentration of the peptide/s
at the relevant receptors might differ from that nominally
applied, due to the size and diffusion of the peptide/s to neu-
rons located at different depths in the brain slice and, possibly,
to the action of extracellular peptidases. Protein kinase inhibi-
tors were applied intracellularly through the patch pipette.
DMSO up to 0.13% did not affect either the sIAHP amplitude
or charge transfer, or the effect of PACAP-27 on the sIAHP
amplitude or charge transfer when applied intracellularly
through the patch pipette as a vehicle to dissolve some protein
kinase inhibitors.
Cells were excluded if the series resistance changed signifi-
cantly (>25%) in the course of experiments. Modulation of
sIAHP was determined as changes in amplitude and charge
transfer of sIAHP. The sIAHP amplitude was measured by calcu-
lating the mean current between two cursors placed 50 ms
apart, 1 s after the initiation of the voltage step to avoid con-
tamination by other, faster potassium currents. Charge transfer
was determined as the area under the curve starting from the
sIAHP peak until full decay had occurred.
Isoproterenol hydrochloride and tetraethylammonium chlo-
ride (TEA) were obtained from Sigma (UK); PACAP-27
amide, SB 203580, phorbol-12,13-dibutyrate (PDBu), bisindo-
lylmaleimide I (BIM-1), and chelerythrine chloride from Cal-
biochem (now Merck Serono Ltd, Middlesex, UK); PACAP-38
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from Peninsula Laboratories Europe (St. Helens, UK); PACAP-
(6–38) from Bachem (Bubendorf, Switzerland); tetrodotoxin
(TTX) from Latoxan (Valence, France); and Rp-cAMPS and 8-
(4-chloro-phenylthio)22’-O-methyl-cAMP (8CPT-O-Me-cAMP)
from BioLog Life Science Institute (Bremen, Germany). Maxadilan
and max.d.4 were a generous gift from Dr. Ethan Lerner at
Harvard Medical School.
Statistical analysis was performed with GraphPad InStat.
Data are presented as mean with error bars indicating the
standard error of the mean (S.E.M.), when not otherwise
specified.
RESULTS
The sIAHP was recorded in the whole-cell patch-clamp con-
figuration from 152 CA1 pyramidal neurons. CA1 neurons had
an average resting membrane potential of 259.86 3.5 mV
(n5 84; mean6 SD) and an input resistance of 175.46 51.1
MX (n5 80; mean6 SD). The sIAHP amplitude was on aver-
age 40.66 24.2 pA and the charge transfer 101.46 63.8 pC
(n5 84; mean6 SD).
PACAP Suppresses sIAHP in CA1 Pyramidal
Neurons
The modulatory effects on the sIAHP of VIP and other neu-
ropeptides that activate the cAMP-PKA pathway in hippocam-
pal pyramidal neurons are well studied (Aldenhoff et al., 1983;
Haas and Gahwiler, 1992; Haug and Storm, 2000). Given the
structural similarity of PACAP and VIP (Miyata et al., 1989;
Miyata et al., 1990) and the fact that they share a subset of
receptors (VPAC1 and VPAC2), coupled to the cAMP-PKA
pathway (reviewed in Vaudry et al., 2009), we hypothesized
that PACAP might suppress sIAHP in hippocampal pyramidal
neurons. We found that PACAP-38 (500 nM) reduced the
sIAHP amplitude (Figs. 1A,C) by 67%6 5.9% (Fig. 1E, n5 7)
and the charge transfer by 77.3%6 5.2% (Fig. 1E, n5 7) in
CA1 pyramidal neurons.
The region responsible for receptor activation of PACAP-38
resides in its N-terminal 27-amino acid sequence, which corre-
sponds to the naturally occurring isoform PACAP-27 (Miyata
et al., 1990). We therefore tested the effect of PACAP-27 (500
nM) on sIAHP. PACAP-27 suppressed sIAHP within 15–20 min
of bath application (Fig. 1B,D), and no reversibility was
observed within 15–35 min of wash-out. PACAP-27 sup-
pressed the sIAHP amplitude by 86.1%6 4.7% and the charge
transfer by 85.8%6 5.1% (Fig. 1E, n5 4). No significant dif-
ference between PACAP-27 and PACAP-38 was found with
regard to the reduction in sIAHP amplitude (P> 0.06, unpaired
t test) and charge transfer (P> 0.3, unpaired t test). We there-
fore decided to use PACAP-27 in the following experiments.
PACAP-27 suppressed the sIAHP in a concentration depend-
ent manner (Fig. 1F). While 100 nM PACAP-27 only slightly
reduced the sIAHP amplitude (29.9%6 10.6%, n5 4), the
FIGURE 1. PACAP-38 and PACAP-27 suppress sIAHP in hip-
pocampal neurons. Averaged current traces (n5 3) of the sIAHP
before (control) and after application of 500 nM PACAP-38 (A)
or 500 nM PACAP-27 (B). Overlaid traces are shown in the right-
most panels (A and B), control (black) and PACAP (grey). The
dashed line corresponds to the baseline current. Time course of
the effect of PACAP-38 (C) and PACAP-27 (D) on the sIAHP
amplitude from the experiments shown in A and B. Bars indicate
the presence of 500 nM PACAP in the bath solution. (E) Effect of
500 nM PACAP-38 (black) and PACAP-27 (white) on sIAHP
amplitude and charge transfer. No significant difference was
observed between the two PACAP isoforms. (F) The effect of
PACAP-27 on sIAHP was concentration-dependent. PACAP-27 sig-
nificantly suppressed sIAHP amplitude at both 250 nM (n5 18,
P< 0.0001) and 500 nM (n5 4, P< 0.01), while at 100 nM
PACAP-27 did not cause a significant inhibition of sIAHP (n5 4,
P> 0.05). The difference between the sIAHP reduction caused by
250 and 500 nM PACAP-27 was not significant (P> 0.05, Dunn’s
multiple comparisons test). (G) PACAP-27 (250 nM) decreased
spike frequency adaptation in a representative CA1 neuron in
response to a current injection of 140 pA, resting membrane
potential5259 mV. Similar effects were observed in seven cells.
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reduction with 250 nM was more substantial (77.4%6 6.7%,
n5 18) and comparable to the effect of 500 nM PACAP-27
(86.1%6 4.7%, n5 4). PACAP-27 at 250 nM caused a sup-
pression of the sIAHP amplitude by more than 90% in 50% of
the neurons (9 out of 18 cells; Fig. 1F). 2 out of 18 cells dis-
played a sIAHP inhibition comprised between 85 and 90%; 2
out of 18 cells between 70 and 75%; 4 out of 18 cells between
40 and 55% (Fig. 1F). In one case, corresponding to 5.6% of
all cells tested, the sIAHP was not affected by 250 nM PACAP-
27 (2.4% inhibition; Fig. 1F). All cells treated with 500 nM
PACAP-27 displayed reductions of the sIAHP amplitude in the
range of 80–100% (n5 4; Fig. 1F).
Beside inhibiting sIAHP, PACAP produced an inward shift in
the holding current at the holding potential of 250 mV, corre-
sponding to a depolarizing effect. PACAP-38 at 500 nM eli-
cited an inward current of 16.06 2.1 pA in 7 out of 7 cells
(n5 7; P5 0.0002). An inward current of 146 3.3 pA
(n5 18; P5 0.0006) was observed in response to 250 nM
PACAP-27 in 16 out of 18 cells. The inward current might be
due to the modulatory action of PACAP on background (leak)
channels, HCN channels, and/or other nonspecific cationic
channels, in analogy to what has been observed for other neu-
rotransmitters inhibiting the sIAHP in hippocampal neurons.
PACAP-27 at 250 nM did not significantly affect the input
resistance of CA1 pyramidal neurons, which was 164.56 9.7 MX
before and 163.96 8.1 MX after PACAP-27 application (n5 18;
P5 0.96, Wilcoxon matched-pairs signed-ranks test).
The inhibition of the sIAHP reduces late spike frequency
adaptation in hippocampal pyramidal neurons (Madison and
Nicoll, 1982; Madison and Nicoll, 1984). Application of 250
nM PACAP-27 reduced spike frequency adaptation in CA1
pyramidal neurons (Fig. 1G, n5 7), in agreement with its
inhibitory effect on the sIAHP.
Activation of PAC-1 Receptors Partially Mimics
the Effect of PACAP on sIAHP
Neuronal PACAP receptors comprise PAC1, selective for
PACAP and coupled to both adenylyl cyclases and phospholipase
C, and VPAC1 and VPAC2 receptors, activated by both PACAP
and VIP and coupled to adenylyl cyclases (Vaudry et al., 2009).
All three PACAP receptor subtypes are expressed in CA1 pyram-
idal cells (Hashimoto et al., 1996; Shioda et al., 1997; Joo
et al., 2004). To elucidate the specific contribution of PAC1
receptors to the PACAP-mediated sIAHP inhibition in CA1
pyramidal cells, we used the PAC1 selective agonist maxadilan, a
peptide structurally unrelated to PACAP (Lerner et al., 1991),
which has no activity at VPAC1 and VPAC2 receptors (Moro
and Lerner, 1997). Maxadilan and PACAP activate PAC1 recep-
tors with a similar potency in the rat brain (Moro et al., 1996).
When tested at 250 nM, the same concentration as used for
PACAP-27, maxadilan reduced the sIAHP amplitude (Figs 2A,B)
by 32.6%6 3.9% (n5 5; P5 0.001, t test) and charge transfer
by 24.4%6 4.7% (n5 5; P5 0.007, t test) (Fig. 2D). This
indicates that PAC1 receptors contribute to the PACAP-induced
suppression of sIAHP in CA1 pyramidal neurons.
To investigate whether the reduction of sIAHP induced by
maxadilan could be prevented by a PACAP receptor antagonist,
we used PACAP-(6–38), a truncated PACAP-38 lacking six
amino terminal amino acids. PACAP-(6–38) is a selective
antagonist at PAC1 and VPAC2 receptors (Dickinson et al.,
1997; Moro et al., 1999). In the presence of PACAP-(6–38)
(500 nM), application of maxadilan (250 nM) did not signifi-
cantly reduce the sIAHP amplitude (5.7%6 10.7%, n5 4,
P> 0.5, t test) or charge transfer (25.3%6 13.6%, n5 4,
P> 0.5 t test) (Fig. 2C,E). The lack of reduction of the sIAHP
FIGURE 2. Selective activation of PAC1 receptors partly
mimics the inhibitory effect of PACAP on the sIAHP. Averaged cur-
rent traces (n5 3) of the sIAHP before (control) and after applica-
tion of the selective PAC1 receptor agonist maxadilan at 250 nM
(A). In the rightmost panel, the traces in the absence (black) and
presence (grey) of maxadilan are superimposed. The dashed line
corresponds to the baseline current. (B) Time-course of the effect
of 250 nM maxadilan on the amplitude of sIAHP. Each point is
the mean6 SEM of five experiments. Application of maxadilan is
indicated by the arrow. (C) 500 nM PACAP-(6–38), a PAC1 recep-
tor antagonist, prevented the effect of 250 nM maxadilan as
shown on averaged current traces (n5 3) of the sIAHP. The dashed
line corresponds to the baseline current. Overlaid traces are shown
in the rightmost panel. Bar charts summarizing the reduction of
sIAHP amplitude and charge transfer by 250 nM maxadilan (D)
and the absence of maxadilan effect in the presence of 500 nM
PACAP-(6–38) (E) in five cells. Error bars indicate S.E.M.
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by a specific PAC1 receptor agonist (maxadilan) in the presence
of a PAC1 receptor antagonist further supports a contribution
by PAC1 receptors.
Surprisingly, the reduction of the sIAHP as a consequence of
PAC1 receptor activation is not supported by the results
obtained upon 250 nM PACAP-27 application in the presence
of PACAP-(6–38). Under this condition, PACAP-27 reduced
the sIAHP amplitude (79.2%6 11.2%, n5 5, P5 0.002, t test)
and the charge transfer (86.8%6 8.5%, n5 5, P5 0.0005, t
test) to a comparable extent (amplitude: P> 0.5, charge trans-
fer: P> 0.3) as observed in the absence of PACAP-(6–38) (Fig.
1). The suppression of sIAHP by maxadilan but the lack of
antagonism of PACAP-27 by PACAP-(6–38) suggests the acti-
vation of more than one receptor subtype in the PACAP-
mediated inhibition of this current.
Max.d.4 is a derivative of maxadilan, in which nineteen
amino acids between positions 24 and 42 are deleted. It is a
selective PAC1 receptor antagonist that is more potent than
PACAP-(6–38) (Moro et al., 1999). In the presence of 500
nM max.d.4, 250 nM PACAP-27 inhibited the sIAHP ampli-
tude (69.8%6 10.8%, n5 4, P< 0.01, t test) and charge
transfer (74.5%6 7.3%, n5 4, P< 0.01, t test) to an extent
that was comparable (amplitude and charge transfer: P> 0.5)
to the effect of PACAP-27 alone (Fig. 1). This further indicates
that antagonism of PAC1 receptors alone is not sufficient to
prevent the PACAP-27 mediated inhibition of sIAHP, which is
instead due to the activation of more than just PAC1 receptors.
PACAP-27 Suppresses sIAHP Partly Through
PKA Activation
In hippocampal neurons monoaminergic neurotransmitters
such as noradrenaline, histamine, serotonin and dopamine
inhibit the sIAHP through PKA activation (Pedarzani and
Storm, 1993, 1995). Moreover, in CA1 pyramidal neurons
CRF, VIP and CGRP have been shown to suppress sIAHP in a
PKA-dependent manner (Haug and Storm, 2000). We there-
fore asked whether PKA was required to mediate the inhibitory
effect of PACAP on sIAHP in hippocampal pyramidal neurons.
To address this question, we used the PKA inhibitor Rp-
cAMPS added to the intracellular solution (Pedarzani and
Storm, 1993). Application of PACAP-27 (250 nM) in the
presence of Rp-cAMPS (500 mM) caused an inhibition of the
sIAHP that was attenuated when compared to the effect of
PACAP-27 alone (Fig. 3A,B). The inhibition of the sIAHP
amplitude was reduced from 77.4%6 6.7% in the absence of
Rp-cAMPS (Figs. 1F and 3C) to 56.8%6 5.9% in the pres-
ence of Rp-cAMPS (Fig. 3C). Similarly, the sIAHP inhibition
by 500 nM PACAP-27 was reduced from 86.1%6 4.7% in
the absence (Fig. 1F and 3C) to 42.7%6 11.1% in the pres-
ence of Rp-cAMPS (Fig. 3C). An inward shift in the holding
current of 16.66 6.8 pA (n5 15; P5 0.002) was observed
upon application of PACAP-27 (250 nM) in the presence of
Rp-cAMPS.
To ensure that Rp-cAMPS inhibited PKA under our
experimental conditions, we used isoproterenol (1 mM), a
b-adrenergic receptor agonist that inhibits the sIAHP by activa-
tion of the cAMP/PKA pathway (Pedarzani and Storm, 1993).
The sIAHP inhibiton caused by isoproterenol (100%6 0.02%,
n5 4) was significantly reduced in the presence of Rp-cAMPS
(41.2%6 8.4%, n5 5, P5 0.0005, unpaired t test). When
isoproterenol was applied after PACAP-27 in the presence of
Rp-cAMPS, the sIAHP was inhibited to 43.1%6 7% (n5 5) of
the amplitude left after PACAP-27 inhibition, showing that
Rp-cAMPS inhibited PKA. These results show that PKA con-
tributes to the PACAP-27-mediated inhibition of the sIAHP.
Are MAP Kinases Involved in the PACAP-27-
Mediated Inhibition of sIAHP?
In a Drosophila mutant PACAP modulates a potassium cur-
rent through the activation of a mitogen-activated protein
(MAP) kinase pathway (Zhong, 1995). PACAP has also been
shown to activate the MAP kinase kinase (MEK)/extracellular-
signal-regulated kinase (ERK) pathway in cultured cerebellar
FIGURE 3. PKA activation contributes to the inhibition sIAHP
by PACAP-27. Averaged current traces (n5 3) of the sIAHP before
and after bath application of 250 nM PACAP-27 in the absence
(upper traces) and in the presence (lower traces) of the PKA inhib-
itor Rp-cAMPS (500 mM) (A). In the rightmost panels, the traces
in the absence (black) and presence (grey) of PACAP-27 are super-
imposed. The dashed line corresponds to the baseline current. (B)
Time course of the normalized sIAHP amplitude from the experi-
ments shown in A before, during, and after PACAP-27 application
in the presence (black squares) and absence (white squares) of
intracellular Rp-cAMPS. Bar indicates the presence of 250 nM
PACAP-27. (C) Bar chart summarizing the effect on the sIAHP
amplitude of PACAP-27 at 250 and 500 nM in the absence (white
bars) and presence (black bars) of Rp-cAMPS. Rp-cAMPS signifi-
cantly reduced the suppression of sIAHP amplitude by PACAP-27
at 250 nM (P5 0.04, n5 15, Mann–Whitney test), and at 500
nM (P5 0.01, n5 5, unpaired t test). The values for sIAHP inhibi-
tion by PACAP-27 at 250 nM (n5 18) and 500 nM (n5 4) in the
absence of Rp-cAMPS are the same as in Figure 1E,F and are
reported here for comparison. Error bars indicate S.E.M. * indi-
cates statistical significance.
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granule cells (Villalba et al., 1997). Furthermore, PACAP-38
activates p38 MAP kinase (p38 MAPK) in mouse cultured cer-
ebellar granule cells (Ster et al., 2007). We therefore asked
whether the effect of PACAP on the sIAHP could be mediated
by the activation of the ERK or p38 MAPK pathway.
To first test for a potential contribution of the MEK-ERK1/
2 pathway, we applied intracellularly the MEK inhibitor
UO126 (40 mM) (Favata et al., 1998). In the presence of
UO126, PACAP-27 (250 nM) inhibited the sIAHP
(58.5%6 8.7%, n5 8) to the same extent as in intercalated
control experiments performed with 0.13% DMSO in the pip-
ette solution (63.1%6 7.1%, n5 6, P> 0.6, Mann–Whitney
test). Similarly, inhibition of MEK by UO126 did not affect
the suppression of sIAHP by 500 nM PACAP-27
(90.2%6 4.4%, n5 6, P> 0.1, Mann–Whitney test).
Next, we tested the hypothesis of an involvement of p38
MAPK in the PACAP-mediated inhibition of sIAHP. In the
presence of SB 203580 (20 mM), a p38 MAPK inhibitor
(Eyers et al., 1998), PACAP-27 (250 nM) partly inhibited the
sIAHP (Fig. 4A). Figure 4B shows the time course of the reduc-
tion in sIAHP amplitude from the experiment in Figure 4A
before, during, and after PACAP-27 application. When com-
pared with experiments performed in the absence of SB
203580, the inhibition of the sIAHP amplitude by PACAP-27
was reduced in the presence of the p38 MAPK inhibitor
(31.3%6 11.2%, n5 7, P5 0.006, Mann–Whitney test, Fig.
4C). Similar experiments were performed with an increased
concentration of PACAP-27 (500 nM). In this case SB 203580
did not reduce the PACAP-27-induced inhibition of the sIAHP
amplitude (70.4%6 11.6%) when compared with the sIAHP
inhibition induced in the absence of the p38 MAPK inhibitor
(n5 5, P> 0.2, unpaired t test). SB 203580 largely prevented
the inward shift in the holding current (4.86 2.9 pA; n5 7;
P5 0.14) caused by PACAP-27 (250 nM).
Taken together, these results indicate that p38 MAPK is
involved in mediating the inhibitory effect of PACAP on the
sIAHP in CA1 pyramidal neurons, while a contribution by the
MEK/ERK1/2 pathway seems unlikely.
Does PACAP Activate p38 MAP Kinase and
PKA in the Same or in Parallel Pathways
Resulting in sIAHP Inhibition?
Both the inhibition of PKA by Rp-cAMPS (Fig. 3) and of
p38 MAPK by SB 203580 (Fig. 4) result in a decrease of the
PACAP-27-induced sIAHP suppression. This prompts the ques-
tion as to whether PACAP-27 activates p38 MAPK and PKA as
part of the same or two parallel pathways leading to sIAHP sup-
pression. If PKA and p38 MAPK operate sequentially as part of
the same pathway, their concomitant inhibition should not have
a stronger impact on the effect of PACAP-27 than inhibition of
each single kinase. Conversely, if PKA and p38 MAPK act
through parallel, independent pathways their combined inhibi-
tion should have a stronger impact on the effect of PACAP-27.
The PKA inhibitor Rp-cAMPS and the p38 MAPK inhibi-
tor SB 203580 were included together in the intracellular solu-
tion, and 250 nM PACAP-27 was applied for 15 min,
causing a partial inhibition of the sIAHP (Fig. 5B). The
PACAP-27-induced inhibition of sIAHP was attenuated in the
presence of Rp-cAMPS and SB 203580 (Fig. 5A). The reduc-
tion of the PACAP-27 effect on the sIAHP upon combined
inhibition of PKA and p38 MAPK was significant compared
with control conditions (51.8%6 4.9%; n5 7; P5 0.02,
Mann–Whitney test; Fig. 5C). However, the PACAP-27-
mediated suppression of sIAHP amplitude observed in the
presence of Rp-cAMPS and SB 203580 was not significantly
different from that observed in the presence of Rp-cAMPS
alone (compare Figs. 5C and 3C) or SB 203580 alone (com-
pare Figs. 5C and 4C) (Kruskal–Wallis Test—nonparametric
ANOVA: P5 0.105). The observation that the combined inhi-
bition of PKA and p38 MAPK does not prevent the PACAP-
27 reduction of the sIAHP to a larger extent than the inhibition
of each single kinase suggests that they act sequentially as part
of the same signal transduction pathway.
cAMP activates not only PKA but also “exchange proteins
directly activated by cAMP” (EPAC) (Rehmann et al., 2003),
which can lead to the activation of small G-proteins and p38
MAPK (Shi et al., 2006; Ster et al., 2007). Activation of p38
FIGURE 4. p38 MAPK activation is involved in the PACAP-
27-induced inhibition of sIAHP. Averaged current traces (n5 3) of
the sIAHP before and after application of 250 nM PACAP-27 in
the absence (upper traces) and in the presence (lower traces) of
the p38 MAPK inhibitor SB 203580 (20 mM) in the intracellular
solution (A). The rightmost panels show superimposed traces in
the absence (black) and presence (grey) of PACAP-27. The dashed
line corresponds to the baseline current. (B) Time course of the
effect of PACAP-27 on the normalized sIAHP amplitude from the
experiments in A, in the absence (white squares) and in the pres-
ence (black squares) of SB 203580. Bar indicates the presence of
250 nM PACAP-27. (C) Bar chart summarizing the relative inhibi-
tion of the sIAHP amplitude by 250 nM PACAP-27 under control
conditions (n5 18; white bar) and in the presence of SB 203580
(n5 7; black bar). SB 203580 markedly inhibited the suppression
of sIAHP mediated by PACAP-27. Error bars indicate S.E.M.
* indicates statistical significance.
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MAPK by EPACs would be in parallel to the one by PKA
(Fig. 8). If indeed PKA and p38 MAPK act sequentially in the
same pathway to mediate the inhibition of sIAHP by PACAP-
27, as suggested by the combined inhibition of PKA and p38
MAPK (Fig. 5), we would expect the EPAC contribution to
this pathway to be minor or negligible. To distinguish between
PKA and EPAC-mediated effects, we applied the highly specific
EPAC superactivator 8CPT-O-Me-cAMP (Rehmann et al.,
2003). 8CPT-O-Me-cAMP (5 mM) reduced the sIAHP ampli-
tude by 10.3%6 5.2% (Fig. 6A–C, n5 7). This reduction was
not significant (P> 0.05). To assess the integrity of the PKA
meditated modulation of the sIAHP we applied to the same
cells the membrane permeable PKA activator 8CPT-cAMP
(Fig. 6A,B). PKA activation by 8CPT-cAMP led to a suppres-
sion of the sIAHP by 92.8%6 3.4% (n5 7, Fig. 6C), showing
the functionality of the PKA pathway. The lack of current inhi-
bition by EPAC activation excludes a contribution by EPACs
to the modulation of the sIAHP. This supports the finding that
PKA and p38 MAPK are arranged sequentially to mediate the
inhibition of the sIAHP by PACAP (Fig. 8).
PKC is not Involved in the sIAHP Inhibition
Mediated by PACAP-27
Besides their coupling to the cAMP/PKA and MAP kinase
pathways, PACAP receptors have been shown to activate phos-
pholipase C (PLC) linked signaling cascades (Spengler et al.,
1993; Harmar, 2001; reviewed in Vaudry et al., 2009). Protein
kinase C (PKC) is generally thought to act downstream of
PLC (Nishizuka, 1992) and its activation suppresses the sIAHP
in hippocampal pyramidal neurons (Malenka et al., 1986). We
therefore investigated whether, beside PKA and p38 MAPK,
also PKC is involved in the sIAHP suppression induced by
PACAP-27.
To obtain maximal PKC inhibition, a combination of two
specific inhibitors acting at different sites on PKC, 20 mM che-
lerythrine (Herbert et al., 1990) and 500 nM bisindolylmalei-
mide I (BIM-1) (Toullec et al., 1991), was applied
intracellularly. Inhibition of sIAHP amplitude (89.3%6 7.7%,
n5 5) by PACAP-27 (250 nM) was not significantly different
compared to recordings performed in the absence of chelerythr-
ine and BIM-1 (Fig. 7A,B, and D; P> 0.3, Mann–Whitney
test). An inward shift in the holding current of 29.76 9.1 pA
FIGURE 5. Simultaneous inhibition of p38 MAPK and PKA
partly prevents the suppression of sIAHP mediated by PACAP-27.
Averaged current traces (n5 3) of the sIAHP in the absence and
presence of 250 nM PACAP-27 recorded without (upper traces)
and with (lower traces) the PKA inhibitor Rp-cAMPS (500 mM)
and the p38 MAP kinase inhibitor SB 203580 (20 mM) in the
patch pipette (A). The rightmost panels display the superimposed
traces in the absence (black) and presence (grey) of PACAP-27.
The dashed line corresponds to the baseline current. (B) Time
course of the effect of PACAP-27 on the sIAHP amplitude from the
experiments in A, with (black squares) and without (white squares)
Rp-cAMPS1 SB 203580. Bar indicates the application of 250 nM
PACAP-27. (C) Bar chart summarizing the relative inhibition of
sIAHP by 250 nM PACAP-27 under control conditions (n5 18;
white bar) and in the presence of Rp-cAMPS1 SB 203580 (n5 7;
black bar). Coapplication of Rp-cAMPS and SB 203580 partly
prevented the suppression of sIAHP amplitude mediated by 250
nM PACAP-27. Error bars indicate S.E.M. * indicates statistical
significance.
FIGURE 6. Activation of EPACs does not suppress sIAHP in
CA1 neurons. Averaged sIAHP traces (n5 3) recorded in the
absence (control) and presence of the EPAC superactivator 8CPT-
O-Me-cAMP (5 mM) and of the PKA activator 8CPT-cAMP (5
mM) (A). The rightmost panel shows the same traces superim-
posed. (B) Time course of action of 8CPT-O-Me-cAMP (5 mM)
and 8CPT-cAMP (5 mM) on the sIAHP amplitude in the same cell
as in A. (C) Bar diagram summarizing the effects of 8CPT-O-Me-
cAMP (5 mM; black bar) and subsequently applied 8CPT-cAMP
(5–50 mM; white bar) on the sIAHP amplitude in seven cells. The
8CPT-cAMP was used at a concentration of 50 mM in 6 out of 7
cells. The suppression of sIAHP caused by 8CPT-cAMP was signifi-
cantly larger than that observed in response to 8CPT-O-Me-cAMP
(P< 0.0001, n5 7, unpaired t test). Error bars indicate S.E.M.
* indicates statistical significance.
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(n5 5; P5 0.03) was observed upon application of PACAP-27
(250 nM) in the presence of the PKC inhibitors. To validate
PKC inhibition under our experimental conditions, we acti-
vated PKC by phorbol-12,13-dibutyrate (PDBu). Under con-
trol conditions, PDBu (500 nM) caused a strong inhibition of
the sIAHP amplitude (74.4%6 3.3%; n5 5), which was signifi-
cantly reduced (34.7%6 15.4%, n5 6, P5 0.04, unpaired t
test) in the presence of chelerythrine (20 mM) and BIM-1
(500 nM). This indicates that PKC was indeed inhibited under
these experimental conditions.
These experiments show that the PKC signaling cascade
does not significantly contribute to the inhibition of the sIAHP
by PACAP.
Is a Crosstalk Between the PKA and PKC
Pathways Involved in the Inhibition of sIAHP by
PACAP?
The lack of PKC involvement in the suppression of the sIAHP
by PACAP inferred from the experiments where only PKC was
inhibited does not entirely exclude the possibility of a function
of PKC in the context of a crosstalk with the PKA/p38 MAPK
pathway. To elucidate this hypothesis we applied PACAP-27 in
the presence of both PKA and PKC inhibitors. The inhibition
of sIAHP by PACAP-27 was reduced to 56.4%6 5.0% in the
presence of Rp-cAMPS, chelerythrine and BIM-1 (Fig. 7C,D;
n5 10, P5 0.03, Mann–Whitney test). The inhibition of the
sIAHP amplitude by PACAP-27 was similar in the presence of
Rp-cAMPS alone and the combination of Rp-cAMPS, cheler-
ythrine and BIM-1 (Fig. 7D; P> 0.8, Mann–Whitney test). By
contrast, inhibition of PKC alone by chelerythrine and BIM-1
with no Rp-cAMPS did not reduce the PACAP effect to a simi-
lar extent (Fig. 7D; P5 0.003 Mann–Whitney test).
These results suggest that the involvement of PKC in the
PACAP-mediated inhibition of the sIAHP is unlikely also as
part of a crosstalk.
DISCUSSION
This study shows that PACAP increases the excitability of
CA1 pyramidal neurons by inhibiting the slow Ca21-activated
K1 current sIAHP through the activation of multiple signaling
pathways, most prominently cAMP/PKA and p38 MAPK. Our
findings reveal a novel modulation of the sIAHP by p38 MAPK
in CA1 pyramidal neurons, adding to the role of this current
as a convergency point for modulatory inputs mediated by
multiple protein kinases in central neurons.
Previous studies have identified the slow afterhyperpolariza-
tion in hippocampal neurons as a target for the neuromodula-
tory actions of several neuropeptides, including CRF
(Aldenhoff et al., 1983; Haug and Storm, 2000), VIP (Haas
and Gahwiler, 1992; Haug and Storm, 2000), and CGRP
(Haug and Storm, 2000). Similar effects on the sIAHP have
been reported for CRF, VIP and PACAP in layer II/III and V
neocortical pyramidal neurons (Hu et al., 2011). Our study
shows that in CA1 pyramidal neurons both PACAP isoforms,
PACAP-38 and PACAP-27, suppress the sIAHP, leading to an
enhancement of intrinsic excitability and attenuation of spike
frequency adaptation. The suppression of the sIAHP by PACAP
shown in our study provides a cellular mechanism for the
increase in spontaneous firing of CA1 neurons observed in vivo
upon application of PACAP-38 (Di Mauro et al., 2003).
CA1 pyramidal neurons express all three types of PACAP
receptors, PAC1, VPAC1 and VPAC2 (Hashimoto et al., 1996;
FIGURE 7. PKC is not involved in the sIAHP suppression
mediated by PACAP-27. Superimposed averaged sIAHP traces
(n5 3) recorded in the absence and presence of 250 nM PACAP-
27 without (top panel) and with (lower panel) the PKC inhibitors
chelerythrine (20 mM) and BIM-1 (500 nM) in the patch pipette
(A). The dashed line corresponds to the baseline current. (B) Time
course of the effect of PACAP-27 on the normalized sIAHP ampli-
tude from the experiments in A, with white squares indicating the
absence and black squares the presence of Chelerythrine1BIM-1.
Bar indicates the application of 250 nM PACAP-27. (C) Averaged
sIAHP traces (n5 3) recorded in the absence and presence of 250
nM PACAP-27 with chelerythrine (20 mM), BIM-1 (500 nM) and
Rp-cAMPS (500 mM) in the patch pipette. The lower panel shows
the traces in the absence (black) and presence (grey) of PACAP-27
superimposed. The dashed line represents the baseline current. (D)
Bar chart summarizing the relative inhibition of sIAHP by 250 nM
PACAP-27 under control conditions (n5 18; white bar; same data
as in Fig. 1F, reported here for comparison) and in the presence of
Chelerythrine1BIM-1 (n5 5; black bar), Rp-cAMPS (n5 15;
grey bar; same data as in Fig. 3C, reported here for comparison),
and Chelerythrine1BIM-11Rp-cAMPS (n5 10; stripy bar).
Chelerythrine and BIM-1 did not prevent the suppression of sIAHP
by PACAP-27 and did not affect the partial inhibition of the
PACAP-27 effect by Rp-cAMPS. Error bars indicate S.E.M. * indi-
cates statistical significance.
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Shioda et al., 1997; Joo et al., 2004). The 30% reduction of
the sIAHP amplitude we observed upon application of the selec-
tive PAC1 agonist maxadilan suggests a potential contribution
of PAC1 receptors. The presence of the PAC1/VPAC2 antago-
nist PACAP-(6–38) (Dickinson et al., 1997; Moro et al.,
1999) indeed prevented the effect of maxadilan, supporting a
potential role for PAC1 receptors. Additionally the activation
of VPAC1, but not VPAC2 receptors, leads to the suppression
of the sIAHP amplitude, because the activation of PAC1 recep-
tors alone by maxadilan is not sufficient to inhibit the sIAHP to
a similar extent as caused by PACAP. The involvement of
VPAC1 receptors was further inferred by the observation that
the PAC1/VPAC2 antagonist PACAP-(6–38) did not prevent
the inhibition of the sIAHP by PACAP. This is different from
what has been observed in the neocortex, where PACAP has
been reported to activate the cAMP/PKA pathway by acting
mainly through PAC1 receptors (Hu et al., 2011). Our study
concludes that the sIAHP suppression by PACAP can be elicited
through the activation of PAC1 and most likely VPAC1 recep-
tors in CA1 pyramidal neurons.
PAC1 and VPAC1 receptors can couple to multiple signal
transduction pathways, often depending on the cell type and
developmental stage. Both receptors activate adenylyl cyclases,
leading to the production of cAMP in a variety of cells. Addi-
tionally, they can activate phospholipase C, leading to the for-
mation of diacylglycerol and inositol trisphosphate, and
phospholipase D (Fig. 8, reviewed in Vaudry et al., 2009).
Because the closely related neuropeptide VIP suppresses the
sIAHP by activating the cAMP/PKA pathway in CA1 pyramidal
neurons (Haug and Storm, 2000) and PACAP has been
reported to do the same in the neocortex (Hu et al., 2011), we
initially expected PACAP to exert its inhibitory action on the
sIAHP predominantly through the same pathway. Surprisingly,
inhibition of PKA by the phosphodiesterase-resistant cAMP
analogue Rp-cAMPS (Botelho et al., 1988) only partially pre-
vented the effect of PACAP on the sIAHP. Interestingly, a simi-
lar partial inhibition by Rp-cAMPS was reported for the effect
of VIP on the sIAHP (Haug and Storm, 2000). The residual
sIAHP inhibition might be a consequence of Rp-cAMPS being
a competitive PKA inhibitor that can be partly displaced by
high levels of cAMP (Botelho et al., 1988). This would mean
that high levels of cAMP, such as those produced by higher
concentrations of PACAP, would weaken the inhibitory effect
of Rp-cAMPS on PKA. However, our observation that Rp-
cAMPS reduced the sIAHP inhibition by higher concentrations
of PACAP if anything more than by low concentrations makes
this an unlikely explanation. Given the coupling of PACAP
receptors to multiple signaling pathways and the modulation of
sIAHP by various protein kinases, including PKA, PKC, and
calcium-calmodulin protein kinase II (reviewed in Stocker
et al., 2004), it is plausible that PACAP suppresses this current
by activating also other pathways beside cAMP/PKA. In neu-
rons PACAP activates two different MAP kinases, ERK1/2 and
p38 (Sakai et al., 2001; Shi et al., 2006; Monaghan et al.,
2008; Stetler et al., 2010). Our data support a significant con-
tribution of p38 MAPK to the PACAP effect on the sIAHP.
Interestingly, the contribution of p38 MAPK is more promi-
nent than that of PKA for the low concentration of PACAP,
while PKA seems to prevail at the high PACAP concentration.
The different impact of p38 MAPK in response to different
PACAP concentrations might reflect the recruitment of differ-
ent signaling pathways by signals of different intensities
(Dumaz and Marais, 2005). Conversely, inhibition of MEK/
ERK1/2 did not affect the inhibition of the sIAHP by PACAP-
27 at any concentration tested. On the basis of our data, we
propose a novel role for p38-MAPK in the modulation of the
sIAHP and intrinsic excitability of CA1 pyramidal neurons.
If PACAP activated the PKA and p38 MAPK pathways in
parallel, their concomitant inhibition should lead to an additive
reduction of the sIAHP suppression. The lack of additive effect
of PKA and p38 MAPK inhibitors in our study suggests that
these two kinases act as part of the same signaling pathway,
rather than being engaged by two separate pathways activated
in parallel by PACAP and converging on the sAHP channels
(Fig. 8). Evidence for a sequential action of PKA and p38
MAPK within the same pathway has been found in various cell
types, where PKA has been proposed to activate p38 MAPK
through an as yet unknown mechanism (Zheng et al., 2000;
Delghandi et al., 2005; Shi et al., 2006). A similar signaling
pathway might indeed underlie the effect of PACAP on the
sIAHP that we have observed in CA1 pyramidal neurons. In
view of the results obtained with PACAP in this study, it will
be interesting to see whether p38 MAPK might contribute to
FIGURE 8. Signal transduction pathway mediating the sup-
pression of sIAHP by PACAP in CA1 pyramidal neurons. Schematic
drawing illustrating the signal transduction pathway mediating the
effect of PACAP on the sIAHP in CA1 pyramidal neurons. Pathway
components supported by the results obtained in our study are
depicted in black; other potential contributors, whose role was
discounted by the results of our experiments, are shown in grey.
AC, adenylyl cyclase; Gs, G-alpha-s heterotrimeric G-protein; Gq,
G-alpha-q heterotrimeric G-protein; PLC, phospholipase C; DAG,
diacylglycerol; IP3, inositol 1,4,5 trisphosphate; MKK, mitogen-
activated protein kinase kinase.
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the neuromodulatory effects also of other neuropeptides and
neurotransmitters. Indeed, p38 MAPK has been shown to
mediate the persistent sAHP suppression caused by prolonged
stimulation of type 5 metabotropic glutamate receptors in CA3
pyramidal neurons (Young et al., 2008).
In other studies, p38 MAPK is a downstream substrate of
the cAMP signaling pathway independent of PKA, through the
activation of exchange proteins directly activated by cAMP
(EPACs) and small G-proteins (Fig. 8, Shi et al., 2006; Ster
et al., 2007). Our results, obtained by using a highly specific
EPAC superactivator (Rehmann et al., 2003), do not support
an involvement of EPACs in the modulation of sIAHP.
PAC1 and VPAC1 receptors are coupled to the phospholi-
pase C (PLC) pathway, leading to the activation of PKC (Fig.
8, reviewed in Vaudry et al., 2009). PKC suppresses the sIAHP
in hippocampal pyramidal neurons (Malenka et al., 1986).
However, our data show that PACAP does not suppress sIAHP
by activating PKC in CA1 pyramidal neurons. This argues in
favor of selective coupling between PACAP receptors and spe-
cific signal transduction pathways in hippocampal neurons.
The basis for this selectivity might lie in the existence of signal-
ing microdomains defining the spatio-temporal dynamics of
PACAP signaling, a topic that will be addressed in future
studies.
In conclusion, our study shows that PACAP effectively mod-
ulates the intrinsic excitability and firing behavior of CA1
pyramidal neurons through the suppression of sIAHP. It is well
established that a reduction in the sAHP in CA1 and CA3
neurons accompanies acquisition of hippocampus-dependent
learning, whereas increases in the sAHP are correlated with
cognitive impairment (reviewed in Disterhoft et al., 2004).
The impact of the sIAHP on learning processes reflects its multi-
ple roles in controlling firing and intrinsic excitability (Zhang
and Linden, 2003) and integration of synaptic signals (Sah and
Bekkers, 1996; Borde et al., 1999; Lancaster et al., 2001; Wu
et al., 2004; Fernandez de Sevilla et al., 2007). Drosophila har-
boring a mutation in the PACAP-related gene amnesiac display
deficits in associative learning (Quinn et al., 1979; Feany and
Quinn, 1995). In the rat, PACAP intracerebroventricular
administration enhances learning, possibly by affecting memory
consolidation (Sacchetti et al., 2001). Mice lacking PAC1
receptors display impaired long-term potentiation (LTP) of
synaptic transmission at several synapses in the hippocampal
formation (Otto et al., 2001; Matsuyama et al., 2003), corre-
lating with a deficit in contextual fear conditioning, a
hippocampus-dependent learning task (Sauvage et al., 2000;
Otto et al., 2001; Matsuyama et al., 2003). PACAP regulates
bidirectional synaptic plasticity at the Schaffer collateral CA1
synapse in a concentration-dependent manner, whereby sub-
nanomolar concentrations of the peptide induce long-lasting
facilitation of excitatory synaptic potentials (Roberto et al.,
2001), while concentrations similar to those used in this study
(250–500 nM) cause either an initial decrease followed by an
enhancement (Roberto et al., 2001), or a long-lasting depres-
sion of excitatory synaptic transmission (Kondo et al., 1997;
Ster et al., 2009) that depends on EPAC and p38 MAPK acti-
vation (Ster et al., 2009). Taken together, our results suggest
that modulation of the sIAHP via PAC1 and VPAC1 receptors
might contribute to the complex effects of PACAP on synaptic
plasticity in the hippocampal formation and ultimately on
learning and memory consolidation.
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